Seikagaku Corporation

Seikagaku Corporation

Share · JP3414000004 (XTKS)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Seikagaku Corporation
No Price
Closing Price XTKS 28.04.2026: 706,00 JPY
28.04.2026 06:30
Current Prices from Seikagaku Corporation
ExchangeTickerCurrencyLast TradePriceDaily Change
XTKS: Tokyo
Tokyo
4548.T
JPY
28.04.2026 06:30
706,00 JPY
4,00 JPY
+0,57 %
Share Float & Liquidity
Free Float 56,15 %
Shares Float 30,66 M
Shares Outstanding 54,6 M
Invested Funds

The following funds have invested in Seikagaku Corporation:

Fund
iShares Core MSCI Japan IMI UCITS ETF USD (Dist)
Vol. in million
11,66
Percentage (%)
0,0063 %
Fund
iShares Core MSCI Japan IMI UCITS ETF EUR Hedged (Acc)
Vol. in million
4,76
Percentage (%)
0,0063 %
Company Profile for Seikagaku Corporation Share
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.

Company Data

Name Seikagaku Corporation
Company Seikagaku Corporation
Website https://www.seikagaku.co.jp
Primary Exchange XTKS Tokyo
ISIN JP3414000004
Asset Class Share
Sector Healthcare
Industry Medical - Devices
CEO Kenji Mizutani
Market Capitalization 39 Mrd.
Country Japan
Currency JPY
Employees 1,0 T
Address Marunouchi Center Building, 100-0005 Tokyo
IPO Date 2004-03-23
Dividends from 'Seikagaku Corporation'
Ex-Date Dividend per Share
30.03.2026 11,95 JPY
29.09.2025 15,00 JPY
28.03.2025 15,00 JPY
27.09.2024 15,00 JPY
28.03.2024 13,00 JPY
28.09.2023 13,00 JPY
30.03.2023 13,00 JPY
29.09.2022 11,00 JPY
30.03.2022 10,00 JPY
29.09.2021 10,00 JPY

Stock Splits

Date Split
28.03.2005 3:2
26.05.2004 3:2

Ticker Symbols

Name Symbol
Tokyo 4548.T
More Shares
Investors who hold Seikagaku Corporation also have the following shares in their portfolio:
Advantis Corp.
Advantis Corp. Share
EQUITY RELEASE FUNDING (NO.4) PLC CMTG BKD DEF INT FRN2049£(VAR)(BR)(REGS)
EQUITY RELEASE FUNDING (NO.4) PLC CMTG BKD DEF INT FRN2049£(VAR)(BR)(REGS) Bond